Two outstanding gene-editing startups, Chroma Drugs and Nvelop Therapeutics, mentioned Wednesday they may merge, forming a brand new firm referred to as nChroma Bio.
The merger will mix molecular machines Chroma was growing to change genes with out chopping DNA and know-how Nvelop was growing to ship DNA-modifying equipment to express tissues within the physique.
Management for the mixed firm argued it was a pure match. In trade parlance, it joins a “supply” firm with a “cargo” firm — fusing the 2 key items wanted to construct a genetic medication.
This text is unique to STAT+ subscribers
Unlock this text — plus day by day protection and evaluation of the biotech sector — by subscribing to STAT+.
Have already got an account? Log in
View All Plans
